Experimental liver cancer drug shows promise in early trial

NCT ID NCT00422877

Terminated Disease control Sponsor: American Regent, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a drug called Taxoprexin (DHA-paclitaxel) in 13 people with advanced liver cancer that had not responded to prior treatments. The goal was to see if the drug could shrink tumors and how safe it was. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Taxoprexin (DHA-paclitaxel)
What this could lead to: If it works, this could point toward a new second-line treatment option for advanced liver cancer.
What could go wrong: This was a very small, early-phase trial that was terminated early, so results are limited and may not be reliable. The drug may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF THE LIVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer carcinoma of liver and intrahepatic biliary tract gallbladder carcinoma hepatocellular carcinoma Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF THE LIVER

Contacts and locations

Locations

University of Texas, MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.